development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies

Takara Bio

09/04/2018 07:35

April 9(Reuters) - Takara Bio Inc  4974.T 
    
    * Says it has entered into an agreement with Otsuka
Pharmaceutical
Co., Ltd for co-development and exclusive sales rights in Japan
for Takara's NY-ESO-1 siTCRTM (TBI-1301, TBI-1301-A) and CD19
CAR (TBI-1501) gene therapies

    
    
    Source text in Japanese:https://goo.gl/YzGkkU
    Further company coverage: 4974.T 

 (Beijing Headline News)
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))